Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

14 Feb 2024

Abstract excerpt

TP53-mutant acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are characterized by chemotherapy resistance and represent an unmet clinical need. Chimeric antigen receptor (CAR) T-cells might be a promising therapeutic option for TP53-mutant AML/MDS. However, the impact of TP53 deficiency in AML cells on the efficacy of CAR T-cells is unknown. We here show that CAR T-cells engaging TP53-deficient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38355749
DOI: 10.1038/s44321-024-00024-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cellsPMID 38355749Read ↗

Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53Semantic proximity Read ↗

Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.Semantic proximity Read ↗

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.Semantic proximity Read ↗

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.Semantic proximity Read ↗

Chemoresistance of <i>TP53</i> mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress responseSemantic proximity Read ↗

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read ↗

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read ↗

The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.Semantic proximity Read ↗

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaSemantic proximity Read ↗

Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.Semantic proximity Read ↗

A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.Semantic proximity Read ↗

Acute myeloid leukemia and the Wnt pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.